/
In vitro & in vivo diagnostic substances company · DE · FY ends Dec · Revenue $30M · 8.35% margin · $3M FCF
Operating margin is thin at 5.97%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 4.3%, steady but not accelerating.
Net debt of $9M represents 7.7x FCF, leverage limits flexibility.
Profitability & Returns
Revenue (TTM)
$30M
▲ +4.3% YoY
Net Income (TTM)
-$545K
▲ +51.8% YoY
Op. Margin
8.35%
▲ +12.2pp YoY
ROIC
5.84%
▲ +6.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$3M
▲ +1236.0% YoY
Op. Cash Flow (TTM)
$4M
▲ +591.6% YoY
Net Debt
$6M
Cash & Equiv.
$7M
5Y CAGR: +12.5%
Continue Research